Next Generation Sequencing (NGS) Market is expected to reach $2.7 Billion By 2017

Next Generation Sequencing is a method used for sequencing genomes at high speed, at low cost and with great accuracy. Also known as second generation sequencing (SGS), NGS has led to a marked revolution in the study of hematological malignancies with a substantial number of publications and discoveries in the recent past. It is associated with significant discoveries regarding disease diagnosis, risk stratification, clonal evolution and therapeutic intervention. In the field of genetic genealogy, this powerful technology of Next Generation Sequencing is poised to provide a limitless insight about the genome, transcriptome, and epigenome of any species. Since its inception of the NGS technology has seen a major transformation in the way scientists extract genetic information from biological systems providing important breakthroughs in the fields of disease research and evolutionary science.

What Next Generation Sequencing does?

1.       Provides a much cheaper and higher-throughput alternative to sequencing DNA than traditional Sanger sequencing.

2.       Facilitates the discovery of genes and regulatory elements associated with disease.

3.       Targeted sequencing allows the identification of disease-causing mutations for diagnosis of pathological conditions.

4.       Provides information on the entire transcriptome of a sample in a single analysis. It offers a strong alternative to the use of microarrays in gene expression studies.

Limitations of NGS:

1.       NGS platforms can cost more than $100,000 in start-up costs, and individual sequencing reactions can cost upward of $1,000 per genome.

2.       lnaccurate sequencing of homopolymer regions (spans of repeating nucleotides) on certain NGS platforms, including the Ion Torrent PGM, and short-sequencing read lengths (on average 200-500 nucleotides) can lead to sequence errors.

3.       Data analysis can be time-consuming and may require special knowledge of bioinformatics to garner accurate information from sequence data.

                                     Source: Source: http://www.oxbridgebiotech.com/

According to a recent market research report by MarketsandMarkets, the global Next Generation Sequencing market was valued at $1.3 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 16.3%. The report categories the global NGS market by Platforms (MiSeq, Illumina HiSeq, 454 Roche, Life Technologies Ion Proton/PGM, by Bioinformatics (RNA-Seq, ChIP-Seq), (SBS, SMRT & Pyrosequencing,), (Diagnostics, Personalized Medicine) & by Geography. It provides the complete analysis of the global NGS market and forecasting up to 2017. Geographically the global market is segmented into North America, Europe, Asia, and Rest of the World, with North America having the highest share, followed by Europe.

According to the research report the next generation sequencing market is set to revolutionize applied markets like diagnostics, personalized medicine, drug discovery, biomarker discovery, and agriculture and animals research. The key players in the NGS market include Illumina (U.S.), Life Technologies (U.S.), 454 Roche (U.S.), and Pacific Biosciences (U.S.). The NGS bioinformatics/data analysis market is lead by players like CLC bio (Denmark), Biomatters (New Zealand), Partek (U.S.), Genomatix (Germany), Knome (U.S.), and DNASTAR (U.S.).

The report can be referred here:
http://www.prweb.com/releases/next-generation/sequencing-market/prweb11264969.htm